Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Rebastinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Rebastinib||DCC-2036||BCR-ABL Inhibitor 27 FLT3 Inhibitor 55 TIE2 Inhibitor 1 VEGFR2 Inhibitor 35||Rebastinib (DCC-2036) inhibits BCR-ABL1 and ABL1 mutations including T315I, and has some activity against TIE-2, FLT3, and VEGFR2, potentially resulting in decreased tumor cell growth (PMID: 21481795, PMID: 31763674).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Carboplatin + Rebastinib||Phase Ib/II||Actionable||In a Phase I/II trial, Rebastinib (DCC-2036) and Paraplatin (carboplatin) combination therapy demonstrated acceptable safety, resulted in a partial response in 4.8% (1/21) and stable disease in 48% (10/21) of patients with advanced solid tumors (Annals of Oncology (2020) 31 (suppl_4): S481-S482; NCT03717415).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03717415||Phase Ib/II||Carboplatin + Rebastinib||A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors||Recruiting||USA||0|